ADU-741: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate 2 dose levels of IV ADU-741 every 21 days in about 42 patients. Janssen has exc...